Novartis Divests Non-Core OTCs, Realigns Consumer Supply Chain
This article was originally published in The Tan Sheet
Executive Summary
Novartis sells six OTC brands, including Bufferin, to focus resources on core consumer health products. The firm also is realigning its consumer health supply chain, including restructuring its Lincoln, Nebraska, manufacturing plant, where the workforce will be cut 40%.
You may also be interested in...
Top OTC Stories 2013: Switch, Consumer Business Divestment Plans
The most-read OTC sector stories in “The Tan Sheet” during 2013 include Sanofi’s switch of Nasacort AQ 24HR, an interview with the former director of FDA’s Division of Nonprescription Clinical Evaluation, and Merck and Novartis each pondering the sale of its consumer health unit.
Top OTC Stories 2013: Switch, Consumer Business Divestment Plans
The most-read OTC sector stories in “The Tan Sheet” during 2013 include Sanofi’s switch of Nasacort AQ 24HR, an interview with the former director of FDA’s Division of Nonprescription Clinical Evaluation, and Merck and Novartis each pondering the sale of its consumer health unit.
Novartis Seems Close to Consumer Health Sale – Analyst
Novartis CEO Joe Jimenez made clear the firm is considering divesting its consumer product, animal health and vaccines and diagnostics business, Sanford and Bernstein analysts say. “It seems that Novartis will be making final decisions with these units fairly soon,” they say.